ondansetron clinical trial formulation + ondansetron marketed formulation
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting
Conditions
Chemotherapy-Induced Nausea and Vomiting
Trial Timeline
Jun 1, 2004 → Sep 1, 2004
NCT ID
NCT00972595About ondansetron clinical trial formulation + ondansetron marketed formulation
ondansetron clinical trial formulation + ondansetron marketed formulation is a phase 1 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT00972595. Target conditions include Chemotherapy-Induced Nausea and Vomiting.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00972595 | Phase 1 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting